Thread: Dyskinesias Study Results from Phase 1/2 NP002 in the Treatment of
View Single Post
Old 12-03-2010, 11:51 AM
CarolynS CarolynS is offline
Member
  
Join Date: Nov 2008
Location: Corning NY
Posts: 304
15 yr Member
CarolynS CarolynS is offline
Member
 
Join Date: Nov 2008
Location: Corning NY
Posts: 304
15 yr Member
Default Dyskinesias Study Results from Phase 1/2 NP002 in the Treatment of
Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease

http://www.prnewswire.com/news-relea...111255279.html

Abraham Lieberman, MD, the study's principal investigator and Director of the Muhammad Ali Parkinson's Center, commented, "NP002 represents an innovative approach to a common side effect in treating Parkinson's disease and has opened up new ideas on how to approach dyskinesias. The early study results of NP002 in patients with Parkinson's show promising trends in reducing dyskinesias and in improving gait. I am encouraged by these results and believe they provide a key piece in understanding and addressing the mechanism of dyskinesias in many of our patients with Parkinson's disease."
CarolynS is offline   Reply With QuoteReply With Quote